GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Other Net Income (Loss)

LakeShore Biopharma Co (LakeShore Biopharma Co) Other Net Income (Loss) : $0.00 Mil (TTM As of Sep. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Other Net Income (Loss)?

LakeShore Biopharma Co's Other Net Income (Loss) for the six months ended in Sep. 2023 was $0.00 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00 Mil.

LakeShore Biopharma Co's quarterly Other Net Income (Loss) stayed the same from Sep. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil) but then increased from Mar. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil).

LakeShore Biopharma Co's annual Other Net Income (Loss) declined from Mar. 2021 ($0.00 Mil) to Mar. 2022 ($0.00 Mil) but then stayed the same from Mar. 2022 ($0.00 Mil) to Mar. 2023 ($0.00 Mil).


LakeShore Biopharma Co Other Net Income (Loss) Historical Data

The historical data trend for LakeShore Biopharma Co's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Other Net Income (Loss) Chart

LakeShore Biopharma Co Annual Data
Trend Mar21 Mar22 Mar23
Other Net Income (Loss)
- - -

LakeShore Biopharma Co Semi-Annual Data
Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Other Net Income (Loss) Get a 7-Day Free Trial - - - - -

LakeShore Biopharma Co Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LakeShore Biopharma Co Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Traded in Other Exchanges
Address
38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629
YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.